| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/28/2013 | EP2630149A1 Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors |
| 08/28/2013 | EP2630146A1 Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt |
| 08/28/2013 | EP2630145A1 Carbonate derivatives for the treatment of cough |
| 08/28/2013 | EP2630144A1 Rho kinase inhibitors |
| 08/28/2013 | EP2630143A1 Processes for the preparation of rivaroxaban and intermediates thereof |
| 08/28/2013 | EP2630141A1 Cathepsin s inhibitor compounds |
| 08/28/2013 | EP2630139A1 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| 08/28/2013 | EP2630138A2 1-(heterocyclic carbonyl)-2-substituted pyrrolidines and their use as fungicides |
| 08/28/2013 | EP2630136A1 Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
| 08/28/2013 | EP2630134A1 Pyridine- 2- derivatives as smoothened receptor modulators |
| 08/28/2013 | EP2630132A1 Pochoxime conjugates useful for the treatment of hsp90 related pathologies |
| 08/28/2013 | EP2630129A1 Quinoxaline derivates |
| 08/28/2013 | EP2630128A1 Viral polymerase inhibitors |
| 08/28/2013 | EP2630127A1 Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| 08/28/2013 | EP2630126A1 Pyrazole compounds acting against allergic, immune and inflammatory conditions |
| 08/28/2013 | EP2630124A1 Tetrahydroquinoline derivatives used as ampk activators |
| 08/28/2013 | EP2630123A1 Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
| 08/28/2013 | EP2630122A1 Arylamide derivatives as ttx-s blockers |
| 08/28/2013 | EP2629851A1 Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| 08/28/2013 | EP2629784A1 A novel herbal oil for controlling blood sugar without risk of hypoglycemea |
| 08/28/2013 | EP2629779A2 Use of storage stable viscous phospholipid depot to treat wounds |
| 08/28/2013 | EP2629778A1 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome |
| 08/28/2013 | EP2629777A2 Bicyclic diamines as janus kinase inhibitors |
| 08/28/2013 | EP2629776A2 Compounds, compositions and methods useful for cholesterol mobilisation |
| 08/28/2013 | EP2629775A1 Sustained-release formulation for injection |
| 08/28/2013 | EP2629774A2 Chemosensory receptor ligand-based therapies |
| 08/28/2013 | EP2629773A2 Chemosensory receptor ligand-based therapies |
| 08/28/2013 | EP2629772A1 Method of treating hemorrhoids using macrocyclic lactone compound |
| 08/28/2013 | EP2629771A1 Use of pi3k inibitors for the treatment of obesity, steatosis and ageing |
| 08/28/2013 | EP2629770A1 Method of treating otitis externa using macrocyclic lactone compound |
| 08/28/2013 | EP2629769A1 Cysteine and food intake |
| 08/28/2013 | EP2629768A1 Sodium 2 -mercaptoethane sulfonate for use in the treatment of lumbar pain |
| 08/28/2013 | EP2629767A1 Amide derivatives of benzene-sulfonanilide, pharmaceutical composition thereof and method for cancer treatment using the same |
| 08/28/2013 | EP2629766A2 Combination therapy |
| 08/28/2013 | EP2629765A1 Methods and compositions for treating pox virus infections with an 1, 4 -naphthoquinone as active agent |
| 08/28/2013 | EP2629764A1 Compositions comprising a filler product and a compound of the tetracycline family used at a subantimicrobial dose |
| 08/28/2013 | EP2629763A1 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| 08/28/2013 | EP2629760A2 Therapeutic nanoparticles with high molecular weight copolymers |
| 08/28/2013 | EP2629758A2 Metal ion nanoclusters |
| 08/28/2013 | EP2629757A2 Brimonidine gel compositions and methods of use |
| 08/28/2013 | EP2629756A1 Pharmaceutical topical composition of mupirocin |
| 08/28/2013 | EP2629632A1 Formulation comprising arginine, use and preparation thereof |
| 08/28/2013 | EP2629617A2 Chemosensory receptor ligand-based therapies |
| 08/28/2013 | EP2629615A1 Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| 08/28/2013 | EP2629614A1 Nematocidal sulfonamides |
| 08/28/2013 | EP2629612A1 Method of treating herpes virus infection using macrocyclic lactone compound |
| 08/28/2013 | EP2629610A1 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
| 08/28/2013 | EP2629609A2 Chemosensory receptor ligand-based therapies |
| 08/28/2013 | EP2629607A2 Antimicrobial polyether and polyol compounds |
| 08/28/2013 | EP2629599A2 Control of pathogens and parasites |
| 08/28/2013 | CN203154592U Chinese and western medicine physical therapy belt for psoriasis |
| 08/28/2013 | CN1955280B Potency regeneration cell and culturing method thereof |
| 08/28/2013 | CN1840051B Pain-stopping gel with musk and its preparation method |
| 08/28/2013 | CN1538951B Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of chemotaxis of polymorphonucleate and mononucleate cells |
| 08/28/2013 | CN103270046A Methods and compositions for treating hemophilia B |
| 08/28/2013 | CN103270043A Process for the preparation of morpholinyl anthracycline derivatives |
| 08/28/2013 | CN103270037A Polymorphs and salts of 6-1h-indol-4-yl)-4-(5- { [4-(1-methylethyl)- 1-pi perazinyl] methyl} -1,3-oxazol-2-group)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders |
| 08/28/2013 | CN103270031A Substituted sodium-1H-pyrazole-5-olate |
| 08/28/2013 | CN103270030A Hydrobromide salts of a pyrazolylaminoquinazoline |
| 08/28/2013 | CN103270026A Bi-heteroaryl compounds as vps34 inhibitors |
| 08/28/2013 | CN103270024A Novel substituted isoquinoline derivative |
| 08/28/2013 | CN103270023A 4- { [ ( pyridin- 3 - Yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
| 08/28/2013 | CN103270018A Calcium-sensing receptor-active compounds |
| 08/28/2013 | CN103269716A Lyophilized viral formulations |
| 08/28/2013 | CN103269704A Heterocyclic compounds and uses thereof |
| 08/28/2013 | CN103269703A Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans |
| 08/28/2013 | CN103269702A Composition and method for treating skin conditions |
| 08/28/2013 | CN103269701A Hsp90 inhibitors for treating non-mall cell lung cancers in wild-<wbr/>type egfr and/or kras patients |
| 08/28/2013 | CN103269700A Picropodophyllin polymorphs b or c for use in cancer therapy |
| 08/28/2013 | CN103269699A Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
| 08/28/2013 | CN103269698A Transdermal therapeutic system for administering an active substance |
| 08/28/2013 | CN103269697A Cysteine and food intake |
| 08/28/2013 | CN103269696A Felbinac-containing external patch |
| 08/28/2013 | CN103269695A Methods for facilitating muscle recovery after a period of disuse using beta-ydroxy-beta-<wbr/>methylbutyrate |
| 08/28/2013 | CN103269694A Pharmaceutical composition |
| 08/28/2013 | CN103269693A Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
| 08/28/2013 | CN103269692A Combinations of beta -3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| 08/28/2013 | CN103269691A Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| 08/28/2013 | CN103269687A Bepotastine compositions |
| 08/28/2013 | CN103269686A Ophthalmic composition for contact lens |
| 08/28/2013 | CN103269685A Aqueous solution of ambroxol |
| 08/28/2013 | CN103269677A Dihydroxyfumaric acid derivatives, and use thereof for bleaching skin |
| 08/28/2013 | CN103269593A Alkylsulfinyl-ubstituted thiazolide compounds |
| 08/28/2013 | CN103269592A Cyclic amine substituted oxazolidinone cetp inhibitor |
| 08/28/2013 | CN103269587A New forms of rifaximin and uses thereof |
| 08/28/2013 | CN103269586A Inhibitors of hepatitis c virus |
| 08/28/2013 | CN103269585A Hypersulfated disaccharides to treat elastase related disorders |
| 08/28/2013 | CN103267852A Application of fibroblast activation protein (FAP) alpha to preparation of pancreatic cancer prognosis kit |
| 08/28/2013 | CN103266009A High-purity walnut alpha-linolenic acid as well as preparation method and applications thereof |
| 08/28/2013 | CN103265594A Garcinia acid amide derivative and preparation method thereof and purpose |
| 08/28/2013 | CN103265593A Icariin derivatives |
| 08/28/2013 | CN103265591A Icariin derivative, and preparation method and application thereof |
| 08/28/2013 | CN103265561A Azlocillin sodium compound, preparation method and medicine composition thereof |
| 08/28/2013 | CN103265560A Gossypol/ cotton ketone derivative and preparation method thereof and application of derivative in anti-tumor medicament |
| 08/28/2013 | CN103265559A Substituted tricyclo-quinone compounds, and preparation method and application thereof |
| 08/28/2013 | CN103265558A Hydrobromic acid prasugrel and pharmaceutical composition and application thereof |
| 08/28/2013 | CN103265543A Inhibiting transient receptor potential ion channel TRPA1 |
| 08/28/2013 | CN103265538A Azole antifungal compound and preparation method and application thereof |
| 08/28/2013 | CN103265537A Antitumor compounds, preparation method and application thereof |
| 08/28/2013 | CN103265535A Antitumor compounds, preparation method and application thereof |